Research programme: recombinant follicle-stimulating hormone therapeutics - Trophogen

Drug Profile

Research programme: recombinant follicle-stimulating hormone therapeutics - Trophogen

Alternative Names: rhFSH-Trophogen; TROP 001

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Trophogen
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ovarian cancer
  • No development reported Female infertility; Male infertility

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Female-infertility in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Male-infertility in USA (Parenteral)
  • 04 Feb 2014 Preclinical trials in Ovarian cancer in USA (unspecified route) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top